Q-omics provides the consensus-scored LCA5L profile across patient tissues and cancer cell-line models. LCA5L expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in LGG. Among the 18 cancer types available for tumor–normal comparison, LCA5L is differentially expressed in 12, with the highest sampling consensus in KICH. Additionally, LCA5L RNA expression shows 20,413 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight LGG, KICH, and UVM as cancer lineages where LCA5L shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LCA5L — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LCA5L survival associations across molecular data types. LCA5L RNA expression shows survival associations in the most cancer types (21), followed by mutation status (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LCA5L RNA expression–survival associations across cancer types. High LCA5L expression shows unfavorable associations in LGG, CHOL, BLCA, KICH, HNSC and KIRC. The LGG Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LGG as the clearest survival context for LCA5L RNA expression.
This table summarizes LCA5L tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for LCA5L. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LCA5L shows lower tumor expression in KICH, THCA and LUSC and higher tumor expression in LIHC, BRCA and BLCA. The KICH box plot shows higher LCA5L RNA expression in normal versus tumor tissue (log2 FC = −1.441, t-test p < 0.001).
This table shows molecular features associated with LCA5L in patient tissues and cancer cell lines. In patient samples, LCA5L shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, LCA5L RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BONE, while CRISPR and shRNA rows add functional-dependency signals in BREAST and BLOOD_Lymphoma.
